IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced that its Compensation Committee granted non-qualified stock options to a newly hired employee on December 2, 2024. The grant includes options to purchase 170,000 shares of common stock at an exercise price of $27.45 per share, matching the closing price on Nasdaq Global Select Market on the grant date.

The options were granted under the company's 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 2, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 170,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $27.45 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302324287.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is the exercise price of IDYA's newly granted stock options on December 2, 2024?

The stock options were granted with an exercise price of $27.45 per share, equal to IDEAYA's closing price on The Nasdaq Global Select Market on the date of grant.

How many shares were included in IDYA's December 2024 inducement grant?

IDEAYA Biosciences granted non-qualified stock options to purchase 170,000 shares of the company's common stock.

What is the vesting schedule for IDYA's December 2024 inducement stock options?

The stock options vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the following three years.